Feasibility study of Capecitabine as adjuvant chemotherapy for stage III colon cancer including RS cancer.
Phase 4
- Conditions
- stage III colon cancer including RS cancer
- Registration Number
- JPRN-UMIN000001444
- Lead Sponsor
- KSCC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 92
Inclusion Criteria
Not provided
Exclusion Criteria
1)Pregnant or nursing 2)Medical history of allergy or hypersensitivity reactions to fluoropyrimidines 3)The past of the internal organ transplant 4)Serious coexisting illness a;severe pulmonary dysfunction b;ileus or colon dysfunction c;uncontrolled diabetes mellitus d;liver cirrhosis e;uncontrolled hypertension f;history of myocardial infarction, unstable angina within 6 months prior to the registration 5)Active synchronous or metachronous malignancy other than carcinoma in situ 6)Uncontrollable infectious disease 7)Not suitable for participating in the study for any other reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the rate of completion of treatment as planned
- Secondary Outcome Measures
Name Time Method Safety Cumulative incidence of Hand-foot syndrome and hepatic dysfunction 3-years disease free survival rate 5-years disease free survival rate 3-years overall survival rate 5-years overall survival rate